BiotechTube

CUDC-907

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Conditions

Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

Trial Timeline

Jul 1, 2016 → May 28, 2019

NCT ID
NCT02674750

About CUDC-907

CUDC-907 is a phase 2 stage product being developed by Curis for Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations. The current trial status is completed. This product is registered under clinical trial identifier NCT02674750. Target conditions include Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations.

What happened to similar drugs?

2 of 20 similar drugs in Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations were approved

Approved (2) Terminated (2) Active (16)
✅Acalabrutinib capsuleAstraZenecaApproved
✅Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + DexamethasoneAmgenApproved
🔄CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
🔄AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + PomalidomideAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02909777Phase 1Completed
NCT02674750Phase 2Completed
NCT02307240Phase 1Completed

Competing Products

20 competing products in Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
mRNA-2416ModernaPhase 2
0
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
VIP152 + BTKiVincerx PharmaPhase 1
11
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
AC220Daiichi SankyoPhase 1
29
Valemetostat TosylateDaiichi SankyoPhase 2
39
LinsitinibAstellas PharmaPhase 2
35
AGS67EAstellas PharmaPhase 1
29
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
39
LenvatinibEisaiPhase 2
35
TazemetostatEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
Eribulin mesylateEisaiPhase 2
35
ME-401Kyowa KirinPhase 1
29
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
36